Clinical Trial: Danish Carvedilol Study in Portal Hypertension

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices

Brief Summary: Patients with large esophageal varices who have not yet experienced bleeding, are normally treated with propranolol, a beta blocking agent that reduces the portal pressure and thereby diminish the risk of bleeding. 20-40% of the patients do not respond to this treatment or have to discontinue the treatment because of side effects. The aim of this study is to evaluate if carvedilol (a combined alfa -beta blocker) has better efficacy and safety than propranolol in lowering the portal pressure in patients with cirrhosis.

Detailed Summary:
Sponsor: Hvidovre University Hospital

Current Primary Outcome: If carvedilol is better than propranolol in lowering portal pressure after 3 months of treatment [ Time Frame: 3 months ]

Original Primary Outcome: If Carvedilol has better efficacy on lowering the portal pressure than propranolol in patients with cirrhosis

Current Secondary Outcome: If the effect of a single dose of propranolol can predict the long term effect of propranolol or carvedilol [ Time Frame: 3 months ]

Original Secondary Outcome:

Information By: Hvidovre University Hospital

Dates:
Date Received: June 27, 2007
Date Started: September 2003
Date Completion:
Last Updated: August 7, 2009
Last Verified: August 2009